XELOX方案与SOX方案在胃癌新辅助治疗中的应用价值

目的 探讨XELOX(卡培他滨+奥沙利铂)方案和SOX(替吉奥胶囊+奥沙利铂)方案治疗晚期胃癌的效果.方法 晚期胃癌患者60例,随机平均分为2组:XELOX治疗组和SOX治疗组.2组均以21天为1个疗程,完成2个疗程治疗评定疗效,并随访观察2组疾病进展时间及生存时间.结果 XELOX方案与SOX方案的总有效率分别为36.67％和46.67％,疾病控制率分别为80.00％和86.67％.2组不良反应发生率比较,差异无统计学意义(P＞0.05).结论 XELOX方案和SOX方案治疗晚期胃癌,临床疗效和安全性相近,且容易被患者耐受,可以作为晚期胃癌患者的有效治疗方案.

Therapeutic Effect of XELOX Regimen and SOX Regimen for Advanced Gastric Cancer

Objective To evaluate the therapeutic effect and safety of XELOX and SOX regimen in the treatment of advanced gastric cancer.Methods 60 patients with advanced gastric cancer were randomly divided into 2 groups:XELOX treatment group and SOX treatment group.2 groups were treated with 21 days as a course of treatment to complete the treatment of the 2 courses of treatment efficacy,and follow-up observation of the 2 groups of disease progression time and survival time.Results The total effective rates of XELOX and SOX were 36.67％ and 46.67％,respectively,and the disease control rates were 80.00％and 86.67％,respectively.There was no significant difference in the incidence of adverse reactions between groups IⅡ and Ⅳ (P ＞ 0.05).Conclusion XELOX program and SOX regimen for advanced gastric cancer have similar clinical efficacy and safety,and are easy tolerated,they can be used as an effective treatment of patients with advanced gastric cancer.